Advertisement
U.S. markets closed
S&P Futures
5,772.00 -4.75 (-0.08%) Dow Futures
42,457.00 -44.00 (-0.10%) Nasdaq Futures
20,064.50 -15.50 (-0.08%) Russell 2000 Futures
2,241.60 -1.60 (-0.07%) Crude Oil
70.63 +0.26 (+0.37%) Gold
2,650.30 -2.20 (-0.08%)
Propanc Biopharma, Inc. (PPCB)
OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
Follow
At close: 12:54PM EDT
| Previous Close | 0.0004 |
| Open | 0.0003 |
| Bid | 0.0003 x 0 |
| Ask | 0.0004 x 0 |
| Day's Range | 0.0003 - 0.0004 |
| 52 Week Range | 0.0003 - 0.0288 |
| Volume | |
| Avg. Volume | 16,336,082 |
| Market Cap | 223,099 |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | 0.00 |
| EPS (TTM) | 0.2300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WirePropanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates "Unprecedented" Interest
MELBOURNE, Australia, August 21, 2024--Two scientific journal articles published by the Company and its research partners reached 10 citations and 4,500 reads, respectively, in August, 2024
Business WirePropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America
MELBOURNE, Australia, August 14, 2024--The proenzymes composition patent is an important part of the IP portfolio covering possible future clinical dosage ranges for PRP
Business WirePropanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
MELBOURNE, Australia, July 17, 2024--"The implication is that PRP will enable PD-L1 non responders to become responders," according to Dr Julian Kenyon, MD, MB, ChB
Advertisement
Advertisement
Advertisement
? 2024 Yahoo. All rights reserved.